MetaADEDB 2.0 @ LMMD
Triprolidine
(CBEQULMOCCWAQT-WOJGMQOQSA-N)
Structure
SMILES
Cc1ccc(cc1)/C(=C\CN1CCCC1)/c1ccccn1
Type(s)
Approved
ATC code(s)
R06AX07
Molecular Formula:
C19H22N2
Molecular Weight:
278.391
Log P:
3.8554
Hydrogen Bond Acceptor:
2
Hydrogen Bond Donor:
0
TPSA:
16.13
CAS Number(s):
486-12-4
Synonym(s)
1.
Triprolidine
2.
Actidil
3.
Pro Actidil
4.
Triprolidine Hydrochloride
5.
Triprolidine Hydrochloride Anhydrous
6.
Triprolidine Monohydrochloride
7.
Triprolidine Monohydrochloride, (Z)-Isomer
8.
Triprolidine Monohydrochloride, Monohydrate
9.
Triprolidine Oxalate
10.
Triprolidine Oxalate, (trans)-Isomer
11.
Triprolidine, (Z)-Isomer
12.
Anhydrous, Triprolidine Hydrochloride
13.
Hydrochloride Anhydrous, Triprolidine
14.
Hydrochloride, Triprolidine
External Link(s)
MeSHD014311
PubChem Compound5282443
BindingDB50292411
ChEBI84116
CHEMBLCHEMBL855
DrugBankDB00427
DrugCentral2763
IUPHAR/BPS Guide to PHARMACOLOGY1228
KEGGdr:D01782
dr:D08648
Therapeutic Target DatabaseD0E8CI
ZINC12503099
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Drug DependenceFAERS: 5US FAERS
2OverdoseFAERS: 3OFFSIDES
US FAERS
3UrticariaFAERS: 3
Canada Vigilance: 1
Canada Vigilance
US FAERS
4Accidental drug intake by childFAERS: 2OFFSIDES
US FAERS
5Amphetamines positiveFAERS: 2OFFSIDES
US FAERS
6Anaphylactic shockFAERS: 2US FAERS
7Cerebrovascular accidentFAERS: 2US FAERS
8Chest PainFAERS: 2
Canada Vigilance: 1
Canada Vigilance
OFFSIDES
US FAERS
9DiplopiaFAERS: 2OFFSIDES
US FAERS
10MalaiseFAERS: 2US FAERS
11PruritusFAERS: 2
Canada Vigilance: 3
Canada Vigilance
US FAERS
12SomnolenceFAERS: 2
Canada Vigilance: 5
Canada Vigilance
US FAERS
13TachycardiaFAERS: 2US FAERS
14Visual ImpairmentFAERS: 2US FAERS
15VomitingFAERS: 2
Canada Vigilance: 1
Canada Vigilance
US FAERS
16Abdominal PainFAERS: 1US FAERS
17AdenoiditisFAERS: 1US FAERS
18AmnesiaFAERS: 1OFFSIDES
US FAERS
19AngioedemaFAERS: 1OFFSIDES
US FAERS
20CryingFAERS: 1US FAERS
21DermatitisFAERS: 1US FAERS
22DizzinessFAERS: 1
Canada Vigilance: 2
Canada Vigilance
OFFSIDES
US FAERS
23Drug abuseFAERS: 1US FAERS
24Drug label confusionFAERS: 1US FAERS
25HypersensitivityFAERS: 1US FAERS
26Inappropriate schedule of drug administrationFAERS: 1US FAERS
27Incorrect drug administration durationFAERS: 1US FAERS
28InflammationFAERS: 1US FAERS
29Intentional product use issueFAERS: 1US FAERS
30PalpitationsFAERS: 1
Canada Vigilance: 2
Canada Vigilance
US FAERS
31PetechiaeFAERS: 1US FAERS
32Pharmaceutical product complaintFAERS: 1OFFSIDES
US FAERS
33PneumothoraxFAERS: 1US FAERS
34PolyarthritisFAERS: 1US FAERS
35Product use issueFAERS: 1US FAERS
36ProteinuriaFAERS: 1US FAERS
37UlcerFAERS: 1US FAERS
38Visual disturbanceFAERS: 1US FAERS
39Abnormal visionOFFSIDES
40AbscessOFFSIDES
41Acid refluxOFFSIDES
42Activities of daily living impairedOFFSIDES
43Acute bronchitisOFFSIDES
44Adnexa uteri massOFFSIDES
45AgitationCanada Vigilance: 1Canada Vigilance
46AmenorrheaOFFSIDES
47ArthritisOFFSIDES
48AstheniaCanada Vigilance: 2Canada Vigilance
49AuraOFFSIDES
50Biopsy tongue abnormalOFFSIDES
51Blood potassium decreasedOFFSIDES
52Blood triglycerides increasedOFFSIDES
53Blurred visionOFFSIDES
54BronchospasmCanada Vigilance: 1Canada Vigilance
55Bunion operationOFFSIDES
56Catheter placementOFFSIDES
57Chest discomfortCanada Vigilance: 1Canada Vigilance
58Chronic ulcerative colitisOFFSIDES
59ColitisOFFSIDES
60CyanosisCanada Vigilance: 1Canada Vigilance
61DebridementOFFSIDES
62Dental abscessOFFSIDES
63DiscomfortCanada Vigilance: 1Canada Vigilance
64Drug addictOFFSIDES
65Drug ineffectiveOFFSIDES
66Dry skinOFFSIDES
67Duodenal UlcerOFFSIDES
68DyspepsiaOFFSIDES
69EczemaCanada Vigilance: 2Canada Vigilance
70Emotional distressOFFSIDES
71Endodontic procedureOFFSIDES
72Erectile dysfunctionCanada Vigilance: 1Canada Vigilance
73Erosive gastritisOFFSIDES
74Eye irritationCanada Vigilance: 1Canada Vigilance
75General physical health deteriorationOFFSIDES
76Genitourinary tract infectionOFFSIDES
77Gingival erythemaOFFSIDES
78GranulocytosisOFFSIDES
79HemiparesisOFFSIDES
80HepatitisOFFSIDES
81HypophagiaOFFSIDES
82Impaired driving abilityOFFSIDES
83Impaired work abilityOFFSIDES
84Life expectancy shortenedOFFSIDES
85MetaplasiaOFFSIDES
86Mononucleosis syndromeOFFSIDES
87Multi-organ disorderOFFSIDES
88Myoclonus7110997CTD
89NauseaCanada Vigilance: 1Canada Vigilance
90Optic NeuritisOFFSIDES
91OsteotomyOFFSIDES
92PeriodontitisOFFSIDES
93Poor peripheral circulationOFFSIDES
94Postmenopausal bleedingOFFSIDES
95Pulmonary function test decreasedOFFSIDES
96Rash erythematousCanada Vigilance: 1Canada Vigilance
97Rhinitis1098524CTD
98Sinusitis7327846CTD
99Soft Tissue InfectionOFFSIDES
100SplenectomyOFFSIDES
101Sudden Cardiac DeathOFFSIDES
102Tardive DyskinesiaOFFSIDES
103Temperature intoleranceOFFSIDES
104Temporal ArteritisOFFSIDES
105TenosynovitisOFFSIDES
106TeratomaCanada Vigilance: 1Canada Vigilance
107Toe operationOFFSIDES
108Tooth ExtractionOFFSIDES
109Uterine PolypOFFSIDES
110melanoma16569656CTD
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120235

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.